The EMPEROR-Reduced and DAPA-HF trials showed that SGLT2 inhibitors benefit HFrEF by reducing HHF, cardiovascular death and slowing renal function decline in chronic kidney disease (CKD) patients [85,86]. Here, SLC5A2 is linked to chronic kidney disease.